Research Progress on Treating Acute Myeloid Leukemia by Midostaurin.
10.7534/j.issn.1009-2137.2015.06.045
- Author:
Yin-Ying WANG
1
;
Wan-Ling SUN
2
Author Information
1. Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
2. Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. E-mail: wanlingsun@live.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myeloid, Acute;
Mutation;
Staurosporine;
analogs & derivatives
- From:
Journal of Experimental Hematology
2015;23(6):1780-1784
- CountryChina
- Language:Chinese
-
Abstract:
FLT3 gene mutations occurred in approximately 30% of acute myeloid leukemia (AML) patients, which is closely associated with the occurrence, development and poor prognosis of AML. The therapy targeting at FLT3 mutations might be a promising treatment for AML. Midostaurin can inhibit the activities of III receptor tyrosine kinase encoded by FLT3 gene, induce cell cycle arrest and has a apoptotic effect on primitive AML cells of FLT3 -mutant, FLT3 wild-type and the expression of FLT3 mutated receptor. In view of this, the association between FLT3 mutations and AML, and research advances and clinical applications of midostaurin on the treatment of AML especially for FLT3 mutated AML, are reviewed.
